A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.

Purpose: To determine the dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of oral topotecan administered weekly in patients with relapsed small cell lung cancer (SCLC).

Patients And Methods: Patients were treated with oral topotecan on days 1, 8, and 15, every 28 days. The dose was escalated by 0.